| Name | Title | Contact Details |
|---|
Axiom is a Yardley, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Most Products Inc is a Plainwell, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
First Smile Home Health Care is a company that provides home health services in Sunland, California, including nursing, therapy, medical equipment, home health aide, and medical social worker services.
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
HealthLynked (OTCQB: HLYK) provides a solution for both patient members and providers to improve healthcare by efficiently exchanging medical information. The HealthLynked Network is a cloud-based platform that allows members to connect with their healthcare providers and take control of their medical data. Members can enter their medications, allergies, past surgeries, and personal health records into one convenient online and secure location. Participating healthcare providers can connect with their current and future patients through the HealthLynked Network. Providers also get the benefit of using HealthLynked marketing tools to communicate with their active and inactive patients to improve patient retention, access accurate patient information, and provide efficient online scheduling.